ANDA 209577, held by Sun Pharm Industries. Bosutinib Monohydrate.
As of Nov 15, 2026, ANDA 209577 (Bosutinib), held by Sun Pharm Industries, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2023 | Original application | Tentative approval |
| Bosutinib400MG · tablet;film coated | Bosutinib Monohydrate | None (tentative approval) |
| BosutinibEQ 100MG BASE · tablet;film coated | Bosutinib Monohydrate | None (tentative approval) |
| BosutinibEQ 500MG BASE · tablet;film coated | Bosutinib Monohydrate | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters